Emerging Researchers National (ERN) Conference

nsf-logo[1]

  • About
    • About AAAS
    • About the NSF
    • About the Conference
    • Partners/Supporters
    • Project Team
  • Conference
  • Abstracts
    • Abstract Submission Process
    • Presentation Schedules
    • Abstract Submission Guidelines
    • Presentation Guidelines
    • Undergraduate Abstract Locator (2020)
    • Graduate Abstract Locator (2020)
    • Faculty Abstract Locator (2020)
  • Travel Awards
  • Resources
    • App
    • Award Winners
    • Code of Conduct-AAAS Meetings
    • Code of Conduct-ERN Conference
    • Conference Agenda
    • Conference Materials
    • Conference Program Books
    • ERN Photo Galleries
    • Events | Opportunities
    • Exhibitor Info
    • HBCU-UP/CREST PI/PD Meeting
    • In the News
    • NSF Harassment Policy
    • Plenary Session Videos
    • Professional Development
    • Science Careers Handbook
    • Additional Resources
    • Archives
  • Engage
    • Webinars
    • Video Contest
    • Video Contest Winners
    • ERN 10-Year Anniversary Videos
    • Plenary Session Videos
  • Contact Us

Optimized Delivery of rAAV into the Rodent CNS

Undergraduate #101
Discipline: Biological Sciences
Subcategory: Microbiology/Immunology/Virology

Ambermarie Dawdy - University of South Florida
Co-Author(s): Christian Schuetz, Dylan Finneran, Joaquin Torello, Amanda Pitre, and Kevin Nash, USF Health Byrd Alzheimer's Institute, FL Joaquin Torello, USF Health Byrd Alzheimer's Institute, FL. Amanda Pitre, USF Health Byrd Alzheimer's Institute, FL. Kevin Nash, USF Health Byrd Alzheimer's Institute, FL.



Angelman syndrome (AS) is caused by a disruption to the Ube3a gene and is a complex genetic disorder that primarily affects the central nervous system (CNS). Since AS is a single gene disorder it could potentially be corrected using gene therapy. However, in order for a gene therapy to be effective we would need to target the majority, if not all, neurons with in the CNS. To this end we are examining viral gene delivery into the CNS of rodents. We have chosen to use recombinant adeno-associated virus (rAAV) because it offers a number of advantages to CNS delivery; including long-term expression, low immunogenicity, infects neurons and has shown safety in a large number of clinical trails. Using various rAAV serotypes and green fluorescent protein (GFP) as a reported gene we will examine different routes of administration, which will vary from invasive (intracranial delivery) to less invasive (intravenous delivery). Level of GFP expression will be measured to determine which route of administration and which serotype offers the best global distribution in the CNS. One to two months after injection the rodents will be euthanized and the brain collected for analysis. In our intracranial injections we examined a number of different sites of administration; Lateral ventricle (virus could potentially cross from CSF into parenchyma), Raphe nuclei and Thalamus which both have significant neuronal connections to many different brain regions. The lateral ventricle injections show transgene expression in a number of brain structures including the hippocampus and cortex but it is rather restricted. Raphe and thalamus injections show significant expression at site of injection but also significant projections into other brain regions including hippocampus, cortex, striatum and cerebellum. The raphe injection seemed to be better than the thalamus and injection at this site could be ideal for a secreted protein molecule to be distributed throughout the brain. Examination of serotypes would indicate that rAAV9 would offer the most robust expression with this administration. With intravenous injections we examined novel rAAV constructs. Immunohistochemical examination of the intravenous injections demonstrated significant neuronal transduction with the published PHP.B vector. This vector shown significant GFP expression with both a ubiquitous promoter and a neuronal specific promoter, thus offering the most potential for a global gene delivery to the CNS. Future research includes other various therapeutic protein injections in order to deliver better distribution throughout the brain to give a better neurocognitive response in rodent models.

Funder Acknowledgement(s): Florida Georgia Louis Strokes Alliance for Minority Participation

Faculty Advisor: Kevin Nash, knash@health.usf.edu

Role: I did the slicing, staining, mounting and analysis of the brains. Also I did cell culture, virus creation and injection along with the immunohistochemistry tests and data analysis that went along with the study.

ERN Conference

The 2022 ERN Conference has been postponed.

Full Notice

What’s New

  • Congratulations to Zakiya Wilson-Kennedy on her 2021 AAAS Fellowship
  • Event Vaccination and Liability Policy
  • Webinars
  • Events|Opportunities
  • AAAS CEO Comments on Social Unrest, Racism, and Inequality
  • Maintaining Accessibility in Online Teaching During COVID-19
  • In the News
  • HBCU/CREST PI/PD Meeting

Conference Photos

ERN Conference Photo Galleries

Awards

ERN Conference Award Winners

Checking In

nsf-logo[1]

This material is based upon work supported by the National Science Foundation (NSF) under Grant No. DUE-1930047. Any opinions, findings, interpretations, conclusions or recommendations expressed in this material are those of its authors and do not represent the views of the AAAS Board of Directors, the Council of AAAS, AAAS’ membership or the National Science Foundation.

AAAS

1200 New York Ave, NW Washington,DC 20005
202-326-6400
Contact Us
About Us

The World's Largest General Scientific Society

Useful Links

  • Membership
  • Careers at AAAS
  • Privacy Policy
  • Terms of Use

Focus Areas

  • Science Education
  • Science Diplomacy
  • Public Engagement
  • Careers in STEM

 

  • Shaping Science Policy
  • Advocacy for Evidence
  • R&D Budget Analysis
  • Human Rights, Ethics & Law
© 2022 American Association for the Advancement of Science